PD-L1 Expression in Non-Small Cell Lung Cancer: Data from a Referral Center in Spain

Anti-programmed cell death (PD1)/ligand-1 (PD-L1) checkpoint inhibitors have improved the survival of non-small cell lung cancer (NSCLC) patients. Additionally, PD-L1 has emerged as a predictive biomarker of response. Our goal was to examine the histological features of all PD-L1 cases of NSCLC anal...

Descripción completa

Detalles Bibliográficos
Autores principales: Saez de Gordoa, Karmele, Lopez, Ingrid, Marginet, Marta, Coloma, Berta, Frigola, Gerard, Vega, Naiara, Martinez, Daniel, Teixido, Cristina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393246/
https://www.ncbi.nlm.nih.gov/pubmed/34441386
http://dx.doi.org/10.3390/diagnostics11081452

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8393246/
https://www.ncbi.nlm.nih.gov/pubmed/34441386
http://dx.doi.org/10.3390/diagnostics11081452

Ejemplares similares